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Background. Feedback mechanisms between interferons α and λ (IFNs) may be affected by single nucleotide
polymorphisms (SNP) in interleukin 28B (IL-28B; IFN-λ3) promoter region and may inﬂuence cytomegalovirus
(CMV) replication.
Methods. We associated IL-28B SNPs with the risk of CMV replication after transplantation. Next, we examined
the effect of IL-28B genotypes on IL-28B, and IFN-stimulated gene (ISG) expression, and CMV replication in human
foreskin ﬁbroblast (HFF) and peripheral blood mononuclear cells (PBMCs).
Results. Transplant recipients with an IL-28B SNP (rs8099917) had signiﬁcantly less CMV replication
(P = .036). Both HFF-cells and PBMCs with a SNP showed lower IL-28B expression during infection with CMV,
but higher “antiviral” ISG expression (eg, OAS1). Fibroblasts with a SNP had a 3-log reduction of CMV replication
at day 4 (P = .004). IL-28B pretreatment induced ISG expression in noninfected ﬁbroblasts, but a relative decrease of
ISG expression could be observed in CMV-infected ﬁbroblasts. The inhibitory effects of IL-28B could be abolished by
siRNA or antagonistic peptides against the IL-28 receptor. In ﬁbroblasts, inhibition of IL-28 signaling resulted in an
increase of ISG expression and 3-log reduction of CMV-replication (P = .01).
Conclusions. We postulate that IL-28B may act as a key regulator of ISG expression during primary CMV in-
fection. IL-28B SNPs may be associated with higher antiviral ISG expression, which results in better replication
control.
Keywords. cytomegalovirus; interferon λ; interleukin 28; solid organ transplantation; immunosuppression;
T-cell priming; innate immune response; adaptive immune response; feedback mechanism; interferon-stimulated gene.
The interferon (IFN)-λ family comprises: interleukin
(IL)-28A, -28B, and -29 and IFN-λ4 [1, 2]. All have
been ascribed antiviral properties similar to IFN-α [3,
4]. In vivo, IFN-λs are mainly secreted by dendritic
cells (DC) and macrophages [2, 5]. Evidence for a po-
tential interaction between IFN-λ and IFN-α was
revealed in genome-wide association studies (GWAS)
of patients with chronic HCV infection. Single nucleo-
tide polymorphisms (SNP) in the IL-28B promoter are
associated with lower rates of HCV clearance in re-
sponse to IFN-α treatment [6–9].These SNPs are divid-
ed according to the frequencies in the population: for
the rs8099917 SNP, TT and for the rs12979860 SNP,
CC represent the most frequently observed genotypes
in whites and Asians (“major” alleles); for rs8099917
SNPs, TG and GG and for rs12979860 SNPs, CT and
TT are termed “minor” allele genotypes [6–9]. These
SNPs potentially impact the binding of transcription
factors and methylation sites [10–13]. Some of these
SNPs may be co-linked with other functional SNPs.
Liver biopsies in patients with chronic HCV infection
indicated that the IL-28B genotype alters IL-28B ex-
pression [14, 15], as well as in peripheral blood
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mononuclear cells (PBMCs) [16]. Minor allele genotypes have
been associated with increased ISG expression, which may
thus inhibit viral replication [17–20]. The role of IL-28B SNPs
in acute viral infection outside of HCV is not understood.
In immunocompromised hosts, such as transplant recipients,
acute CMV infection is associated with high morbidity [21, 22].
Immunosuppression contributes signiﬁcantly to the loss of
CMV-speciﬁc adaptive immune control [23]. In this context
the role of innate immunity to control CMV replication is mag-
niﬁed. CMV has evolved many ways to modulate the innate and
adaptive immune response [24]; in particular, modulation of the
IFN-α and its associated pathway have been described [25].
Whether IFN-λ contributes to innate responses, in the context
of acute CMV infection is not known. Transplant recipients
who are CMV-seronegative and receive an allograft from a
CMV-seropositive donor (D + R−) are at highest risk of
CMV-associated morbidity. These patients routinely undergo
antiviral prophylaxis [22]. However, after prophylaxis discon-
tinuation they also present a unique opportunity to study the
course of primary CMV infection [26].
We aimed to explore the effect of IL-28B SNPs on acute CMV
infection and innate immune signalling. In addition, we exam-
ined the impact of IL-28B on CMV-speciﬁc T-cell priming. De-
tailed knowledge of these control mechanisms in the context of
primary CMV infection have implications for the clinical prac-
tice of CMV-disease prevention, utilization of antiviral therapy




Solid organ transplant patients at high risk for CMV replication
(D + R−) were enrolled at the University of Alberta. CMV vire-
mia was monitored after discontinuation of prophylaxis by
quantitative polymerase chain reaction (PCR), measuring plas-
ma CMV DNA level [27] (Supplementary Figure 1A). Healthy
volunteers were recruited for T-cell priming experiments. The
study protocols were approved through local ethics committees
and written informed consent was provided.
IL-28B Promoter Region Polymorphism Genotyping
SNP genotypes were determined using Taqman probes on a
7900HT Fast Real-Time PCR system (Life Technologies).
Probes for the rs12979860 SNP (ABI Assay ID AHS0QIE)
were published elsewhere [28]. This probe set discriminates
the C and T alleles, where C is the major and T is the minor
allele. Probes for the rs8099917 SNP were designed using the
Taqman assay design tool (ABI Assay ID AH1RU99). At this
locus, T predicts the major allele, whereas G predicts the
minor allele. Samples including positive controls were run in
duplicate.
Cells and Cell Cultures
Human foreskin ﬁbroblasts (HFF) from ATCC (HS97FS,
SCRC1041, and CCD1112SK, Supplementary Table 1A) and
peripheral blood mononuclear cells (PBMCs) were grown
in standard media. PBMCs were isolated as published
elsewhere [29].
Cytomegalovirus and Plaque Assay
We used the laboratory adapted Towne strain of CMV for all
assays. To determine viral growth we infected HFF cells and
treated them as described in the individual experiments. Cells
and supernatant were harvested postinfection. Then, we used
standard 14-day plaque assays to determine viral growth.
IL-28A, IL-28B, and IL-29 Speciﬁc Primers and Probes
IL-28B primers/probe were designed based on human interleu-
kin-28B (IFN-λ3), IL-28A (IFN-λ2), and IL-29 (IFN-λ1) mes-
senger RNA (mRNA) sequences using Primer3 Input (version
0.4.0; http://frodo.wi.mit.edu/). Supplementary Table 1B shows
all primers and probes (Integrated DNA technologies). Specif-
icity was tested against expression plasmids containing com-
plete IFNλ1-3 (Invitrogen, puno1-hil28a/28b/29) [2] (data
not shown).
mRNA-expression Proﬁle: IFN-α/β/λ, Pro- and Anti-
inﬂammatory ISGs
RNA was extracted and after reverse transcription, mRNA ex-
pression was quantiﬁed using a real-time PCR approach using
10 ng of complementary DNA (cDNA) per reaction. Expres-
sion proﬁles were normalized to controls (media) and hypoxan-
thine phosphoribosyltransferase (HPRT) using the Pfafﬂ
method [30]. The following primers and probes were used
(TaqMan gene expression assays): Interferon alpha-2 (IFNα2,
Hs00265051_s1), Interferon beta-1 (IFNβ1, Hs01077958_s1),
MX1 (Hs00895608_m1), OAS1 (Hs00973637_m1), IFIT2 (Hs
00533665_m1), ISG15 (Hs01921425_s1), SOCS1 (00705164_
s1), USP18 (Hs00276441_m1), HPRT (Hs01003267_m1), and
IL-28RA (Hs00417120_m1). In the case of no signal at 40 cycles
in unstimulated samples, a CT value of 40 was set as detection for
relative mRNA expression.
ELISA IFN-α
IFN-α levels in supernatants were quantiﬁed by an in-house en-
zyme-linked immunosorbent assay (ELISA) using commercial-
ly available antibodies and a human IFN-α standard (PBL
Biomedical Laboratories). The detection limit was 4.7 pg/mL.
siRNA Transfection
Small interfering RNA (siRNA) against IL-28B and IL-28RA
was used at a concentration of 25 nM (Mission siRNA,
EHu065311-20 µg; negative control, mission siRNA SIC001-
10 μMol; IL-28B SRSI-hs01-00171730, all Sigma). Lipofectamin
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(RNAiMax, Invitrogen) was used for transfection according to
the manufacturer.
Western Blots
Proteins were harvested using RIPA lysis buffer (Santa Cruz Bio-
technology). Samples were loaded at 10 μg of protein/lane in
standard loading buffer to a discontinuous (4.0%/7.5%)
Laemmli/SDS-PAGE gel. Standard running conditions and
wet transfer were used. Primary antibodies against IL-28B and
IL-28RA (Abcam), and against STAT2, and phosphorylated-
STAT2, and GAPDH (RnD), followed by secondary HRP-
conjugated antibodies (Santa Cruz Biotechnology).
Design of IL28 Antagonistic Peptides
Based on previous publications [31, 32] of the crystal structures
of IL-29 and the receptor IL-28RA (PDB: 3OG4, 3OG6), we de-
termined the amino acid residues, which are in close proximity
to mediate interaction between the 2 molecules. We used the
crystal structure of IL-28B oligomer (PDB: 3HHC [31]) focus-
ing on amino acids, whose residues may be involved in the in-
teractions responsible for the formation of the oligomeric state.
We then designed peptides (Supplementary Table 1C) to mimic
these interaction domains in order to prevent the formation of
oligomers.
Flow Cytometry
Prior to surface staining, LIVE/DEAD staining was performed
(near-IR; invitrogen). Markers for identifying T-cell subsets
were CD3, CD4, CD8, CD45RA, and CD69. Monocytes were
labelled with CD14, MHC-II, CD40, and CD86 (all antibodies
from Biolegend or eBiosciences). For T-cell expansion experi-
ments, PBMCs were labelled with Cell Trace Violet proliferation
dye (Invitrogen). Stimulation was according to the respective
experimental condition for 5 days in 5%CO2 at 37°C.
Statistical Analysis
Statistical analyses were performed using SPSS (version 18.0, Chi-
cago) and GraphPad Prism (version 4.0, La Jolla). Categorical var-
iables were evaluated using a χ2 test. Data were nonnormally
distributedaccording toShapiro–Wilk testing; therefore, continuous
variables between 2 groups were evaluated with a Mann–Whitney
U test. A 2-tailed P-value of <.05 was considered signiﬁcant.
RESULTS
Transplant Recipients (D + R−) With Major-allele Genotype
Show More CMV Replication Within the First Year Post
Transplant
We recruited 38 D + R− patients at high risk for CMV primary
infection. Table 1 shows details of patient characteristics. Geno-
typic distribution is comparable to that of the general popula-
tion (data not shown; [6–9]). The duration of antiviral
prophylaxis, allograft types, immunosuppression, patient age,
and gender were comparable across groups. In accordance
with guidelines all D+/R− patients received antiviral prophylax-
is [22]. Interestingly, after stopping antiviral prophylaxis, CMV
replication was detected signiﬁcantly more often in transplant
recipients with a major-allele genotype in rs8099917 (TT vs
TG/GG 45% vs 22% P = .036; OR 5.62 95% CI, 1.02–31.10;
Table 2). Figure 1B illustrates a Kaplan–Meier analysis compar-
ing patients with major (TT) and minor allele genotypes (TG or
GG). For the rs12979860 SNP a trend was observed for more
CMV replication in the major allele genotype (CC vs TT, 52%
vs 0%; P = .089; Table 3). In addition, we analyzed the data
without the multivisceral and heart transplant recipients. Al-
though the power of the study was reduced, a strong statistical
trend remained for the rs8099917 (P = .1) and rs12979860
(P = .09) SNPs.
Human Foreskin Fibroblasts With Major-allele Genotype Show
Higher CMV Replication and Lower CMV-induced ISG
Expression
Next, we used HFF cells as a model system for CMV replication.
HFF cells harboring different IL-28B genotypes were used to
Table 1. Baseline Characteristics and Genotype Distribution
Characteristic Measure or Criteria N = 38
Age, years Median (IQR) 47.5 (22)
Gender Male 29 (76.3%)
Female 9 (23.7%)




Small bowel 1 (2.6%)
Kidney and pancreas 4 (10.5%)
Multivisceral 1 (2.6%)
CMV replication 17 (44.7%)
Age, gender, type of transplant, and rate of CMV replication. Age in years
indicates the age at the time of enrolment into the study. CMV replication
indicates active CMV replication within 12 months of antiviral prophylaxis
discontinuation.
Abbreviations: CMV, cytomegalovirus; IQR, interquartile range.





TT 12 (55%) 15 (45%) 27
TG or GG 9 (77.8%) 2 (22.2%) 11 0.036
21 17 38
Transplant recipients with a minor allele (GT or GG) genotype experienced less
CMV replication.
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investigate the dynamics of CMV infection in vitro (Supple-
mentary Table 1A). We focused on the manifestations of the
IL-28B SNP rs12979860 (CT or TT), because HFF cells carrying
rs8099917 SNPs (TG or GG) were not available via ATCC, and
we could not recruit HFF cells from newborns in our center.
IL-28 receptor α-subunit (IL-28RA) expression was constant
during CMV infection (Figure 1C–E). CMV growth curves
indicated that the major-allele genotype was associated with
3- log10 higher CMV replication at day 4 when compared
with the minor allele (P = .004, Figure 2A).
To further characterize the effect of the rs12979860 SNP, we
measured IFN-λ and IFN-α2 mRNA expression in HFF cells.
HFF cells with a major-allele genotype (CC) had higher
IL-28B mRNA expression during CMV infection compared to
minor-allele genotypes (CT or TT) (Figure 2B). In contrast to
IL-28B, IFNα2 mRNA- expression was lower during CMV in-
fection in HFF cells with the major-allele genotype (CC) com-
pared to minor-allele genotype (CT or TT). Although IFN-α2
mRNA-expression peaked 6 hours after CMV infection, the dif-
ference between genotypes was maximal at 12 hours and 24
hours (Figure 2C).
IFN-α2 and ISG expression are associated. Therefore, we ex-
amined the expression of 2 sets of antiviral ISGs: MX1, OAS1,
IFIT2, and ISG15 were compared to anti-inﬂammatory ISGs:
USP18 and SOCS1 in each of the HFF cells during CMV infec-
tion. Interestingly, the cell line with the major allele genotype
Figure 1. A, Study design: CMV replication after stop of antiviral prophylaxis. Patients (n = 38) at high risk for CMV primary infection were prospectively
recruited. After discontinuation of standard Ganciclovir/Valganciclovir prophylaxis, CMV replication was monitored using a preemptive strategy during a 1-
year follow-up period. B, CMV replication after transplantation according to IL-28B genotype. Cox regression indicates that patients carrying a minor allele in
rs12979860 (TG or GG; dotted line) show less primary CMV-replication after transplantation compared to patients carrying a major-allele (TT, solid line).
C–E, Protein and mRNA expression of IL-28RA during CMV-infection. C, Western blot of HFF-cells with IL-28RA, CMV- immediate early 1(IE1) and beta-
Tubulin. HFF cells were infected (CMV Towne, MOI 0.3) for 2 hours and compared to noninfected (ni) cells, washed and incubated for 48 hours prior to
receptor expression measurement. Western blot of a representative experiments is shown. D, Relative IL-28RA mRNA expression normalized to beta-Tubulin
is shown. Eight independent experiments were performed. No signiﬁcant differences in IL-28RA expression were observed between CMV infection and
noninfection. E, mRNA expression proﬁle of IL-28RA in HFF during stimulation with polyI:C. HFF cells were pretreated with recombinant IL-28B (10 ng/mL
and 100 ng/mL) before stimulation with polyI:C (50 μg/mL). mRNA expression is normalized against HPRT and non-IL-28B treated expression. No signiﬁcant
modulation of IL-28RA upon different IL-28B dosages was observed. Abbreviations: CMV, cytomegalovirus; HFF, human foreskin ﬁbroblast; HPRT, hypoxan-
thine phosphoribosyltransferase; IL, interleukin; mRNA, messenger RNA.
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(CC) had lower levels of antiviral ISGs (Figure 2D–E) and high-
er levels of anti-inﬂammatory ISGs (Figure 2F ). In HFF cells
with the major allele, IFIT2 expression was induced approxi-
mately 6-fold less by CMV infection; conversely, USP18 was in-
duced 3-fold more.
Interferon-λ Pretreatment of HFF Cells Results in Lower IFN-α2
Signaling and Pro-inﬂammatory ISG Induction in Response to
CMV Infection
Because we observed a correlation between IL-28B genotype
and antiviral response in HFF cells, we determined the effects
of exogenously added recombinant IFN-λs. The purpose of
this was to mimic a strong “major allele”-like situation. We ob-
served a dose-dependent inhibitory effect of IFN-λs pretreat-
ment on CMV-induced IFN-α2 mRNA expression in HFF
cells (SCRC1041, CT genotype; Figure 3A). In addition, we ob-
served a strong suppressive effect on antiviral ISG expression
during CMV infection by IL-28B (Figure 3B). In contrast,
anti-inﬂammatory ISGs (USP18 and SOCS1), remained up-
regulated at later time-points of infection in HFF cells pretreat-
ed with IL-28B (Figure 3C). Supplementary Figure 1A illustrates
the induction of ISGs based solely on IFN-λ treatment in non-
infected HFF cells (Supplementary Figure 1A). These ﬁndings
highlight that IFN-λ induces ISGs, but in the context of CMV





CC 10 (48%) 11 (52%) 21
TT 3 (100%) 0 (0%) 3 0.089
13 11 24
Transplant recipients with a minor-allele genotype (TT) showed a trend to less
CMV replication.
Figure 2. IL-28B SNP in ﬁbroblasts reduces CMV replication by increased CMV-induced IFN-α and reduced IFN-λ responses. HFF cells with different
IL-28B genotypes (HS97FS rs12979860: CC, rs8099917: TT; SCRC1041 rs12979860: CT, rs8099917: TT; and CCD1112SK rs12979860: TT, rs8099917: TT)
were infected with human CMV (Towne strain, MOI 0.3). mRNA expression is relative to HPRT and non-infected controls, and 3 independent experiments
were performed unless otherwise indicated. Bars or symbols indicate median value, whiskers the interquartile ranges unless otherwise indicated. The
rs8099917 was the same for all tested cell lines (major allele genotype). A, CMV replication in HFF cells measured with plaque assays. Supernatants were
collected at day 4 from 9 individual experiments. Viral growth was determined using plaque assays as described, and viral load is expressed as plaque-
forming units (PFU) per mL of supernatant. B, IFN-λ mRNA-expression of infected ﬁbroblasts. IL-28A, IL-28B, and IL-29 mRNA is expressed at 24 hours. C,
IFN-α2 mRNA expression of stimulated or infected ﬁbroblasts. In addition to infection (as previously described), a stimulation with poly I:C (50 μg/mL) was
performed. mRNA expression of IFN-α2 is shown at 12 hours. D, Proinﬂammatory ISG response (IFIT2 and OAS1) during CMV infection of HFF cells. E,
Proinﬂammatory ISG response (Mx1 an ISG15) during CMV infection of HFF cells. F, Anti-inﬂammatory ISG response (SOCS1 and USP18) during infection
and stimulation of HFF cells. Same infection condition as previously describe were used, but in this experiment stimulation was performed with transfected
poly I:C (7.5 μg/mL). Abbreviations: CMV, cytomegalovirus; HFF, human foreskin ﬁbroblast; IFN, interferon; IL, interleukin; ISG, IFN-stimulated gene; mRNA,
messenger RNA.
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infection IL-28B effects extensive modulation of net ISG
expression.
Because SOCS-1 inhibits signaling via the IFN-α/β receptor
[33, 34], we determined the effect of IFN-λs on STAT2-
phosphorylation. Pretreatment of HFF cells with recombinant
IFN-λs for 8 hours, followed by a resting phase of 16 hours,
and then 30 minutes IFN-α2 treatment. IL-28B reduced
IFN-α2 induced STAT-2 phosphorylation by 60% (MWU
P = .06; Figure 3D, Supplementary Figure 1B).
Inhibition of Interferon-λ Signaling Increases Pro-inﬂammatory
ISG Expression and Reduces CMV Replication
Since pre-incubation of HFF cells with IFN-λ resulted in decreased
IFN-α2 signaling and decreased pro-inﬂammatory ISG expression
in response to CMV infection, we determined whether inhibition
of IFN-λ signaling could result in the converse situation—
increased ISG expression and lower CMV replication. These ex-
periments were performed in cells with a CT genotype background
(SCRC1041). Transfection of siRNA against IL-28RA resulted in
reduction of IL-28RA expression in HFF cells compared to control
siRNA (Supplementary Figure 1C and 1D). Down-regulation of
IL-28RA had a signiﬁcant effect on CMV replication compared
to negative control siRNA (P = .007). We observed a decline in
CMV replication by a median of greater than a 2-log10 at day-4
post-infection (Figure 4A). This effect was not caused by toxicity
due to transfection of siRNA (MTT-assay, data not shown).
Consistent with our previous experiments, inhibition of IFN-λ
signaling using siRNA resulted in a greater induction of pro-
inﬂammatory ISGs during CMV infection (Figure 4B).
In addition, we designed peptides with the purpose of mod-
ulating IL-28A/B and IL-29 induced signaling via the inhibition
of interactions with IL-28RA (Figure 4C–H). The peptides were
screened based on their ability to inhibit IL-28B signaling. Pep-
tides PRT, LKY, and LNC (10 μM) were added to HFF cells for 2
hours, followed by a 30 minutes challenge with IL-28B (100 µg/
mL). Signaling was assessed by STAT2-phosphorylation
through Western blot. Peptides LKY and LNC lead to a 40%
and 34% reduction in STAT2-phosphorylation, respectively.
Figure 3. Effects of IFN-λ on IFN-α induced signaling in ﬁbroblasts. mRNA expression is relative to HPRT and noninfected controls, and 3 independent
experiments were performed unless otherwise indicated. Bars or symbols indicate median value, whiskers the interquartile ranges unless otherwise in-
dicated. IFN-λ (100 ng/mL) was added 2 hours prior to infection with CMV (MOI 0.3). Data from 3 independent experiments are shown. A, Effects of IFN-λs
on IFNα-response during infection of HFF-cells. mRNA expression is shown 6 hours after infection. B, Effect of IFN-λ on pro-inﬂammatory ISG expression
during CMV infection. mRNA-expression proﬁle is shown 24 hours after infection. C, Effect of IFN-λ on anti-inﬂammatory ISG expression during CMV
infection. mRNA expression is shown 24 hours after infection. D, Effects of IFN-λ on STAT-phosphorylation during IFNα-receptor activation. HFF cells
were pretreated with IFN-λ for 8 hours, then washed and rested for another 16 hours. Finally, IFN-α2 (10 IU/mL) was added to the cells for 30 minutes
prior to harvesting. Abbreviations: CMV, cytomegalovirus; HFF, human foreskin ﬁbroblast; IFN, interferon; IL, interleukin; ISG, IFN-stimulated gene; mRNA,
messenger RNA.
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Peptides REV, FKG, and APP (10 μM) were pre-incubated with
recombinant IL-28B (100 ng/mL) for 2 hours before being
added to HFF cells for 30 minutes. None of these peptides
blocked STAT-2 phosphorylation (Figure 4I, Supplementary
Figure 1E ). Consistent with the ability to inhibit signaling by
IL-28B, pretreatment of HFF cells with peptide LNC resulted
in 2.5 log10 lower CMV-replication at day 4 after infection
(MWU, P = .01; Figure 4J).
The IL-28B SNP and Recombinant IL-28B Modulate IFN
Responses in PBMCs and Inhibit T-cell Priming During CMV-
infection
Successful control of virus-replication is induced and main-
tained by monocytes, T- and B-cells. In order to further exam-
ine the effect of IL-28B, PBMCs from healthy donors were
in vitro stimulated with CMV. IL-28B mRNA expression
was 2000-fold higher in PBMCs from rs8099917 and/or
Figure 4. Stimulatory effects of IFN-λ signaling inhibition. siRNA transfection against IL-28RA and IL28B (25 nM) and respective control siRNA (25 nM)
for 72 hours prior to infection with CMV (Towne, MOI 0.03). Bars show median values, whiskers indicate interquartile ranges. mRNA expression is nor-
malized to HPRT and non-antigen control siRNA. A, Effects of siRNA against IL-28RA and IL-28B on the replication of CMV in ﬁbroblasts. Harvest of cell
culture supernatants at day 4. Determination of viral growth using plaque assays. B, Effects of siRNA induced suppression of IL-28B and its receptor IL-28RA
subunit on pro-inﬂammatory ISGs. Down-regulation of IL-28B and its receptor was associated with an increase in pro-inﬂammatory ISGs expression com-
pared to negative control siRNA. C–H, Design of peptides with potential to interfere with the IL-28RA pathway. Interaction of the IL-29 natural ligand with
IL-28RA is shown. In color different fragments serving as backbone for the blocking peptides is shown. I, Blocking potential of peptides. Peptides PRT, LKY,
and LNC (10 μM) were preincubated for 2 hours with HFF cells, washed, and were challenged with IL-28B (100 ng/mL) for 30 minutes. Peptides REV, FKG,
APP were preincubated for 2 hours with IL-28B and added to HFF1 for 30 minutes. Proteins were harvested and STAT2 phosphorylation was determined
relative to STAT2 and β-tubulin and expressed as percent of respective DMSO controls. Data of 3 independent experiments. Peptide LKY, LNC, and APP were
dissolved in 0.2% DMSO, whereas the other peptides were dissolved in water (a representative Western blot is shown in Supplementary Figure 1E ). Pep-
tides were excluded from further characterization if they independently activated STAT2-phosphorylation (data not shown) J, Effects of blocking peptides on
CMV replication in ﬁbroblasts. HFF cells were pretreated for 2 hours with peptides (10 μM) and respective DMSO control (ctrl). CMV replication was de-
termined at day 4 using plaque assays. Abbreviations: CMV, cytomegalovirus; DMSO, dimethyl sulfoxide; HFF, human foreskin ﬁbroblast; IFN, interferon; IL,
interleukin; ISG, IFN-stimulated gene; mRNA, messenger RNA; siRNA, small interfering RNA.
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rs12979860 major-allele carriers following stimulation with
CMV compared to minor-allele carriers (Figure 5A).
PBMCs from donors with a minor-allele genotype exhibited
a 10-fold higher mRNA-expression of IFN-α2 following CMV
stimulation compared to minor-allele genotypes (Figure 5B).
IFN-α expression was not accounted for by differences in
plasmacytoid dendritic cells, gender, and age (data not
shown). As observed in HFF-cell lines, major-allele carriers dis-
played lower antiviral ISG expression during CMV stimulation
compared with minor-allele carriers (Figure 5B). Pretreatment
with IL-28B (100 ng/mL) for 2 hours prior to stimulation with
CMV suppressed antiviral ISG expression at later time points,
Figure 5. Modulating effects of IL-28B and IL-28B SNPs on interferon responses and on adaptive immune functions during T-cell priming. PBMCs from
healthy volunteers were stimulated with CMV (MOI 0.3). IFN-λ and ISG mRNA-expressions was determined A and B, mRNA was normalized to HPRT
expression and relative fold increases were calculated to non-stimulated controls. Bars indicate median values, whiskers interquartile range values. Com-
parison between 4 major-allele carriers and 4 minor-allele carriers are shown. A, CMV induced IFN-λ mRNA expression according to IL-28B genotype.
mRNA-expression is shown 6 hours after stimulation. B, Stimulatory effect of CMV on pro-inﬂammatory ISG mRNA expression according to genotype. IFNα2
mRNA-expression is shown 6 hours later, and MX1 and OAS1 mRNA expression are shown at 72 hours time point. C, Effect of IL-28B on pro-inﬂammatory
ISG expression. PBMCs were pretreated for 2 hours with recombinant IL-28B (100 ng/mL) and then stimulated with CMV (MOI 0.3). MX1, OAS1, IFIT2, ISG15
mRNA-expression is shown at 72 hours irrespective of the IL-28B genotype. Comparisons between 7 individuals are shown. D, Effects of pretreatment of
PBMC with peptides on CMV stimulated IFN-α production. Irrespective of the IL28B genotype, PBMC from healthy volunteers (n = 5) were pretreated with
peptides (10 μM) for 2 hours prior to stimulation with CMV (MOI 0.3). IFNα levels were determined by ELISA at 24 hours. IFNα is shown as fold change
compared to non-peptide treated controls. E, Effects of pre-treatment of PBMC with peptides on CMV stimulated ISG mRNA expression. Relative ISG
expressions of MX1, OAS1, and IFIT2 were pooled in a proﬁle for every single treatment condition (a separation is shown in Supplementary Figure 2A).
F, Impact of IL-28B on antigen presentation and co-stimulatory signaling of monocytes. PBMCs from CMV seronegative healthy blood donors were pre-
treated with recombinant IL-28B (100 ng/mL) prior to a 5-day stimulation with CMV (MOI 0.05). Relative MFI expression of CD86, HLA DR, CD40 and CD14 is
shown normalized to noninfected and non-pretreated ﬁbroblast lysate (raw data of the experiment is provided in Supplementary Figure 2B). G, Impact of
IL-28B on priming of naive T cells. PBMCs from CMV seronegative healthy volunteers were pretreated with recombinant IL-28B (100 ng/mL) prior to a 5-day
stimulation with CMV (MOI 0.3). T-cell proliferation during in vitro priming with CMV is expressed in percent of the overall respective CD4 T-cell population.
H, Impact of IL-28B on T-cell activation after expansion phase. T cells of different subtypes show a clear down-regulation of CD69 surface expression.
Abbreviations: CMV, cytomegalovirus; ELISA, enzyme-linked immunosorbent assay; HFF, human foreskin ﬁbroblast; IFN, interferon; IL, interleukin; ISG,
IFN-stimulated gene; mRNA, messenger RNA; PBMC, peripheral blood mononuclear cells; siRNA, small interfering RNA.
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providing more evidence that this effect is IL-28B dependent
(Figure 5C, Supplementary Figure 1F).
In order to further explore the modulatory impact of IL-28B,
we used our antagonistic peptides to pretreat PBMCs for 2
hours prior to 24 hours CMV stimulation. Peptide LNC result-
ed in a 2.4-fold induction of IFN-α2 production measured by
ELISA. In addition, the same peptide induced a panel of anti-
viral ISGs (MX1, OAS1, and IFIT2) by more than 6-fold
compared to respective negative controls (MWU, P = .001)
(Figure 5D–E). Supplementary Figure 2A shows mRNA expres-
sion changes for individual ISGs (Supplementary Figure 2A).
IL-28B Impairs Priming of the Adaptive Immune Response to
CMV
Given that IFN-α2 is an important cofactor in activating anti-
gen-presenting cells and promoting antigen presentation to
T cells [35],we determined the impact of IL-28B onmonocyte acti-
vation, and priming of T cells in PBMCs of CMV-seronegative
healthy nonimmunsuppressed blood donors. Pretreatment with
recombinant IL-28B prior to CMV stimulation showed a clear
trend to reduce CD40 and HLA-DR expression on monocytes
(CD14+, Figure 5F, Supplementary Figure 2B) and B cells
(CD20+, data not shown). CD40 is a crucial co-stimulatory fac-
tor for T cells and provides activation signals for monocytes
[36] and B cells [37].
IL-28B was associated with a signiﬁcant reduction of naive
T-cell priming during in vitro CMV stimulation (P = .03,
Figure 5G). The inhibitory effect during the priming phase
was reﬂected by a signiﬁcant reduction of naive CD4+
CD45RA- T-cell proliferation (>50%) during stimulation with
CMV over 5 days. In addition, this important T-cell subset,
which later conﬁgures the memory compartment, had a notable
down-regulation of CD69 (median >30%), an important T-cell
activation marker (Figure 5H).
DISCUSSION
This study provides novel insight into the interplay between
IFN-α and IFN-λ in the context of CMV infection. We demon-
strate that IL-28B may act as a key regulator of ISG expression
and plays a role in T-cell priming during acute CMV infection.
Transplant recipients at high-risk for primary CMV infection,
who carry a minor-allele genotype, showed less CMV replica-
tion during the ﬁrst year following transplantation. Employing
detailed in-vitro and ex-vivo analysis we propose that IL-28B it-
self, and the IL-28B SNP mediate this clinical observation via a
modulation of IFN signalling, induced interferon-stimulated
genes, and T-cell priming (Figure 5).
Recently, in hematopoietic stem cell transplant recipients
with a high risk for CMV primary infection, the IL-28B
minor allele genotype was associated with a lower risk of infec-
tion as well as shorter episode of CMV replication [38]. These
data highly support our hypothesis. In contrast, the IL-28B
minor-allele genotype is known to negatively inﬂuence HCV
treatment outcomes [6–9]. Interestingly, several studies ob-
served an elevated ISG expression in chronic HCV minor-allele
carriers [17–19, 39–41]—giving rise to 2 potential interpreta-
tions. First, HCV is exposed to a generally higher baseline
ISG expression favouring selection of resistant quasi-species
[20]. Second, a higher set-point of ISG impedes a signiﬁcant in-
duction with IFN-α treatment.
Interestingly, in liver transplant patients with a minor-allele
phenotype in graft and recipient the initial viral RNA level at
HCV recurrence is signiﬁcantly lower, suggesting a phase of su-
perior antiviral control [42, 43]. The somewhat surprising asso-
ciation of higher ISG expression in patients with a minor-allele
genotype suggests a feedback between IFN-λ and IFN-α.
Host cells induce IFN-α, IFN -β, and IFN-λ during CMV in-
fection [44, 45].However, the complex role of IFN-λ in the con-
text of CMV replication and its interplay with other IFNs is
incompletely characterized. Our in vitro experiments show
that in ﬁbroblasts, the minor-allele genotype was associated
with reduced CMV replication. Fibroblasts with a minor-allele
genotype showed signiﬁcantly lower IL-28B mRNA expression
during CMV infection. Interestingly, this was associated with
higher IFN-α and antiviral ISG expression. We demonstrated
that treatment with IL-28B reversed these effects and sup-
pressed IFN-α and antiviral ISGs during CMV infection. The
induction of anti-inﬂammatory ISGs likely inhibits STAT2-
phosphorylation [33, 46]. A recent study conﬁrmed that prim-
ing of hepatocytes with IL-29 impaired IFN-α induced STAT
phosphorylation via USP18 [46]. In hepatocytes stimulated
with IFN-λ and IFN-α, an overlap of ISG induction was ob-
served; however, striking differences were present in the array
and duration of induced genes [47, 48]. Interestingly, IFN-λ in-
duced anti-inﬂammatory genes, such as SOCS1, to a much
greater extent than IFN-α [47].
The IL-28 receptor (IL-28RA) transmits the regulatory effects
of IFN-λ. Therefore, we were interested in the potential of IL-
28RA blockade. We suppressed the IFN-λ signalling by reduc-
ing the ligand-receptor interaction using siRNA knockdown of
the IL-28RA. This resulted in signiﬁcantly increased ISG ex-
pression and reduced CMV replication. One limitation is that
transfection with siRNA in itself may change IFN expression,
even though each experiment was performed with a concurrent
negative control siRNA. Also, we designed peptides able to bind
and inhibit the IL-28RA. Pretreatment of HFF-cells with block-
ing peptides resulted in increased antiviral ISGs and reduced
CMV replication.
Aside from the important functions of the innate immune
system, the adaptive immune response is also crucial in efﬁ-
ciently controlling virus replication. CMV-speciﬁc naive
T cells have an important role in the control of primary CMV
infection [23]. We provide strong evidence that the adaptive
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immune response during primary CMV infection might be
modulated by IFN-λ. In particular, naive T cells are inhibited
in their proliferative potential and activation state. Interestingly,
blockade of the “IL-28-receptor” markedly reduced the
RSV-mediated suppression of CD4 T-cell proliferation [49].
Although T cells do not express IL-28RA receptor on the cell
surface, the effect of IL-28B may be transmitted via monocytes,
which show signiﬁcant IL-28RA expression (data not shown).
Our data suggest that IL-28B regulates HLA-DR and CD40
expression on monocytes in the context of CMV-stimulation.
Both antigen presentation and co-stimulatory signalling to
naive T cells are critical elements in the priming phase.
A limitation of this study is the relatively low number and
heterogeneity of patients included. However, this unique patient
group of transplant recipients at highest risks for primary CMV
infection presents the rare opportunity to study the inﬂuence of
innate immune variations. The clinical implication of these
ﬁndings will have to be conﬁrmed in other cohorts. We exclud-
ed seropositive solid organ transplant recipients as the immu-
nological processes to CMV reactivation are different, and
therefore these patients may show a different outcome. CMV
has DNA proof-reading, therefore the accumulation of ISG re-
sistance mutations is less frequent compared to RNA viruses
(see discussed above). In a R+ patient, latent infection is already
established, and the control of virus replication in this situation
has different requirements [23].
Although, post-translational modiﬁcations of ISG-mRNA
could occur, we demonstrate that IFN-λ inhibits the down-
stream signalling of IFN-α. Additionally, the blockade of
IL-28RA signalling by differing means and the use of a plaque
assay to measure CMV replication provides robust data regard-
ing the importance of these pathways. IFN-α or IFN-λ speciﬁc
ISGs should be identiﬁed using microarray expression proﬁles
and might help to further dissect the down-stream effects. An-
other limitation is the cell types and CMV strains used in this
study: further evaluation could be performed using different
strains of CMV (including clinical isolates) and different cell
lines such as endothelial cells. In addition, performing in-
vitro experiments using cells from the transplant recipients
may provide additional supportive data. Finally, we were unsuc-
cessful in obtain an HFF-cell line with the rs8099917 SNP, and
it would be important for future studies to further analyse the
in-vitro effects of this SNP, perhaps by screening other sources
of ﬁbroblasts such as newborn foreskins, in order to obtain one
with this SNP.
In summary, we have demonstrated that immunosuppressed
patients carrying the minor-allele IL-28B SNP have superior
control of CMV replication following primary infection. IL-28B
speciﬁcally inhibited IFN-α-induced ISG expression and hin-
dered the priming of CMV-speciﬁc T cells. These ﬁndings
stand to have a considerable impact upon the clinical manage-
ment of CMV screening and prophylaxis in immunosuppressed
patients. Finally, manipulation of the IFN-λ pathway can prove
valuable in terms of augmenting adaptive immune responses,
such as those required for effective vaccination.
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